Small molecule · Inhibitor of Enhancer of zeste homolog 2 (EZH2) · developed by Pfizer
Mevrometostat (PF-06821497) is an orally available small molecule that selectively binds to and inhibits EZH2, the catalytic subunit of polycomb repressive complex 2. By preventing methylation of histone H3 on lysine 27, it alters gene expression patterns and reduces proliferation of EZH2-expressing cancer cells. It is being studied in metastatic castration-resistant prostate cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06629779 | Phase 3 | Metastatic Castration-Resistant Prostate Cancer | Active not recruiting | PFE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Metastatic Castration-Resistant Prostate Cancer
See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PFE catalysts and pipeline →